• About ApaTech
• Company Profile
• Technology
• The Science of Actifuse
• The Evidence of Actifuse
• Actifuse Clinical Case Series
• Pipeline and Product Development

Pipeline and Product Development

ApaTech is committed to fully demonstrating the clinical superiority of its technology and has a range of comparator clinical studies ongoing in multiple European countries and the USA. In particular Actifuse is being tested against the 'gold standard' bone graft materials, autograft, rhBMPs and against other approaches. The Company has a range of line extensions in development or pending regulatory approval, all aimed at making the surgeon's utilization easier and to extend the range of indications for the products. In addition, ApaTech has continuing in house and academic collaborations to develop a range of more biologically active ceramic bone graft substitutes, and weight-bearing applications.